1. Home
  2. ZDAI vs CVKD Comparison

ZDAI vs CVKD Comparison

Compare ZDAI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZDAI

Primega Group Holdings Limited Ordinary Shares

HOLD

Current Price

$2.91

Market Cap

16.2M

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$4.44

Market Cap

15.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZDAI
CVKD
Founded
2022
2022
Country
Hong Kong
United States
Employees
33
N/A
Industry
General Bldg Contractors - Nonresidential Bldgs
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.2M
15.3M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
ZDAI
CVKD
Price
$2.91
$4.44
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
87.7K
57.8K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$4.15
52 Week High
$11.48
$15.99

Technical Indicators

Market Signals
Indicator
ZDAI
CVKD
Relative Strength Index (RSI) 56.69 39.09
Support Level $0.30 $4.21
Resistance Level $4.10 $5.99
Average True Range (ATR) 0.35 0.44
MACD 0.15 -0.07
Stochastic Oscillator 74.14 20.40

Price Performance

Historical Comparison
ZDAI
CVKD

About ZDAI Primega Group Holdings Limited Ordinary Shares

DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: